Forte Biosciences, Inc.
FBRX
$18.31
-$0.78-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.18M | 2.96M | 3.43M | 2.12M | 2.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.38M | 11.58M | 16.12M | 7.35M | 8.63M |
| Operating Income | -18.38M | -11.58M | -16.12M | -7.35M | -8.63M |
| Income Before Tax | -17.68M | -11.25M | -15.66M | -7.16M | -8.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.68M | -11.25M | -15.66M | -7.16M | -8.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.68M | -11.25M | -15.66M | -7.16M | -8.39M |
| EBIT | -18.38M | -11.58M | -16.12M | -7.35M | -8.63M |
| EBITDA | -18.37M | -11.56M | -16.11M | -7.34M | -8.62M |
| EPS Basic | -0.99 | -0.96 | -1.37 | -1.17 | -4.54 |
| Normalized Basic EPS | -0.62 | -0.60 | -0.86 | -0.73 | -2.84 |
| EPS Diluted | -0.99 | -0.96 | -1.37 | -1.17 | -4.54 |
| Normalized Diluted EPS | -0.62 | -0.60 | -0.86 | -0.73 | -2.84 |
| Average Basic Shares Outstanding | 17.79M | 11.74M | 11.40M | 6.13M | 1.85M |
| Average Diluted Shares Outstanding | 17.79M | 11.74M | 11.40M | 6.13M | 1.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |